Table of Content

Introduction
Executive Summary
CAR-T: Overview
• CAR-T - Overview
• Potential Mechanisms of CAR-T Cell-Mediated Toxicity
• Cytokine Release Syndrome
• Advances in Research of CAR-T Cell Therapy for Solid Tumors
• Global Landscape of CAR-T Cell Therapy
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
CAR-T – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• CAR-T companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CAR-T Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II)
• Comparative Analysis
JNJ-68284528: Janssen Research & Development, LLC
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
LCAR-B38M CAR-T Cell: Nanjing Legend Biotech Co.
• Product Description
• Research and Development
• Product Development Activities
CD30.CAR-T: Tessa Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Early Stage Products (Phase I)
• Comparative Analysis
IM21 CAR-T cells: Beijing Immunochina Medical Science & Technology Co., Ltd.
• Product Description
• Research and Development
• Product Development Activities
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Research programme: CAR-T cell therapy - Endocyte/Seattle Childrens Research Institute
• Product Description
• Research and Development
• Product Development Activities
Research programme: chimeric antigen receptor T cell therapies - CRISPR Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Inactive Products
Comparative Analysis
• CAR-T Key Companies
• CAR-T Key Products
• CAR-T- Unmet Needs
CAR-T- Market Drivers and Barriers
• CAR-T- Future Perspectives and Conclusion
• CAR-T Analyst Views
• CAR-T Key Companies
Appendix



List of Figures


Figure 1 Total Products for CAR-T
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

 

List of Tables


Table 1 Total Products for CAR-T
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products